Design Therapeutics, Inc. Stock Split Ratio
Design Therapeutics, Inc. (DSGN) reported Stock Split Ratio of 61.35% for the 1-month period ending 2021-03-31, per its 10-K filed 2023-03-14.
Discontinued › Notes
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2023-03-14
- 2021-03-31: Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month 61.35%.
- 2020-02-29: Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month 500.00%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio 1 month |
|---|---|
| 2021-03-31 | 61.35% 10-K · filed 2023-03-14 |
| 2020-02-29 | 500.00% 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |